Nicox: Fourth Quarter 2024 Financial and Business Summary

Nicox, the ophthalmic company, has enrolled the last patient in its NCX 470 Denali Phase 3 clinical trial. Results from the trial are expected in the third quarter of 2025. The company generated revenue of €13.7 million for the fourth quarter of 2024, primarily from the sale of future VYZULTA royalties.

As of December 31, 2024, Nicox's cash position stood at €10.7 million, following a debt repayment of €5.2 million. Nicox expects to be funded until the third quarter of 2025, the date of the first results of the Denali study. However, this funding is subject to meeting revenue and cost forecasts.

Financing options are being evaluated to support the development and commercialization of NCX 470. Nicox continues its efforts to secure new partnerships in key markets, particularly in the United States.